Skip to main content

Table 2 Adjusted mean change in WPAI, Work Functioning Impairment Scale, DAS28-ESR, and QOL measures at week 52

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

  PWs or HWs TCZ-SC group csDMARDs-alone group Difference between
TCZ-SC group − csDMARDs-alone group (95% confidence interval)
P value
(TCZ-SC group vs csDMARDs-alone group)
WPAI
 OWI (%) PWs −18.9 −19.0 0.1 (−6.3, 6.5) 0.978
 Presenteeism (%) PWs −17.7 −17.2 −0.5 (−6.7, 5.6) 0.868
 Absenteeism (%) PWs −7.1 −6.0 −1.1 (−4.8, 2.7) 0.580
 Activity impairment (%) Overall −22.3 −15.8 −6.4 (−10.7, −2.2) 0.003
PWs −22.5 −19.4 −3.1 (−8.8, 2.7) 0.293
HWs −24.0 −14.5 −9.5 (−16.0, −2.9) 0.005
Work Functioning Impairment Scale
 WFun PWs −3.2 −3.2 0.0 (−1.3, 1.3) 0.983
Disease activity
 DAS28-ESR Overall −2.732 −1.388 −1.344 (−1.601, −1.087) < 0.001
PWs −2.576 −1.577 −0.999 (−1.386, −0.612) < 0.001
HWs −2.953 −1.279 −1.674 (−2.050, −1.298) < 0.001
 CDAI Overall −13.932 −10.340 −3.591 (−5.440, −1.742) < 0.001
PWs −12.951 −11.679 −1.272 (−3.484, 0.939) 0.259
HWs −15.399 −9.427 −5.972 (−8.964, −2.980) < 0.001
 SDAI Overall −16.014 −11.521 −4.494 (−6.528, −2.459) < 0.001
PWs −14.117 −12.338 −1.778 (−4.163, 0.607) 0.143
HWs −18.391 −11.388 −7.003 (−10.507, −3.499) < 0.001
QOL
 FAI HWs 1.8 0.7 1.0 (0.0, 2.1) 0.054
 EQ-5D Overall 0.147 0.092 0.055 (0.023, 0.086) < 0.001
PWs 0.154 0.123 0.031 (−0.015, 0.077) 0.182
HWs 0.162 0.075 0.087 (0.036, 0.137) < 0.001
 HAQ-DI Overall −0.355 −0.238 −0.117 (−0.207, −0.027) 0.011
PWs −0.349 −0.286 −0.063 (−0.176, 0.050) 0.274
HWs −0.381 −0.226 −0.155 (−0.305, −0.005) 0.042
 K6 Overall −2.2 −1.1 −1.2 (−1.8, −0.6) < 0.001
PWs −1.9 −1.2 −0.6 (− 1.3, 0.0) 0.065
HWs −3.0 −1.1 −1.8 (−2.9, −0.8) < 0.001
  1. Adjusted-weight analysis by inverse probability treatment weighting method
  2. Last observation carried forward method was applied for missing data due to patient discontinuation
  3. CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, FAI Frenchay activities index, HAQ-DI health assessment questionnaire disability index, HW house worker, K6 6-item Kessler psychological distress scale, OWI overall work impairment, PW paid worker, QOL quality of life, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale, WPAI work productivity and activity impairment questionnaire